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Summary
What is known and objective: Drugs with anticholinergic properties increase the risk 
of falls, delirium, chronic cognitive impairment, and mortality and counteract procho-
linergic medications used in the treatment of dementia. Medication review and opti-
misation to reduce anticholinergic burden in patients at risk is recommended by 
specialist bodies. Little is known how effective this review is in patients who present 
acutely and how often drugs with anticholinergic properties are used temporarily 
during an admission. The aim of the study was to describe the changes in the anticho-
linergic cognitive burden (ACB) in patients admitted to hospital with a diagnosis of 
delirium, chronic cognitive impairment or falls and to look at the temporary use of 
anticholinergic medications during hospital stay.
Methods: This is a multi- centre observational study that was conducted in seven dif-
ferent hospitals in the UK, Finland, The Netherlands and Italy.
Results and discussion: 21.1% of patients had their ACB score reduced by a mean of 
1.7%, 19.7% had their ACB increased by a mean of 1.6%, 22.8% of DAP naïve patients 
were discharged on anticholinergic medications. There was no change in the ACB 
scores in 59.2% of patients. 54.1% of patients on procholinergics were taking an-
ticholinergics. Out of the 98 medications on the ACB scale, only 56 were seen. 
Medications with a low individual burden were accounting for 64.9% of the total 
burden. Anticholinergic drugs were used temporarily during the admission in 21.9% 
of all patients. A higher number of DAPs used temporarily during admission was as-
sociated with a higher risk of ACB score increase on discharge (OR = 1.82, 95% CI for 
OR: 1.36- 2.45, P < .001).
What is new and conclusion: There was no reduction in anticholinergic cognitive burden 
during the acute admissions. This was the same for all diagnostic subgroups. The anticho-
linergic load was predominantly caused by medications with a low individual burden. 
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1  | WHAT IS KNOWN AND OBJEC TIVE
The increasing age of the population is a success of individual 
and public health that unfortunately goes hand in hand with mul-
timorbidity and polypharmacy. Of specific concern are prescrip-
tion and over- the- counter medications that have anticholinergic 
activity. These include a wide variety of drugs including those for 
hypertension, cardiovascular and pulmonary disease. Over the 
last 25 years, there has been increasing evidence that cholinergic 
blockade in the central nervous system has been linked to adverse 
effects such as confusion, behavioural disturbances, reduced ex-
ecutive and motor functions, altered emotions1-5 and increased risk 
of falls, delirium, chronic cognitive impairment and mortality.6-9 An 
age- related increase in permeability of the blood- brain barrier is 
thought to contribute to this problem.10 The use of multiple drugs 
with drugs with anticholinergic properties (DAPs) is thought to 
have an additive effect. The cumulative anticholinergic cognitive 
burden (ACB) of all therapies predicts more accurately the risk 
of adverse events.11 Acetylcholinesterase inhibitors (AChE- I) are 
used in the treatment of mild- to- moderate Alzheimer’s disease.12 
Up to 60% of patients with dementia are reported to receive at 
least one anticholinergic drug.13,14 The combination of both pro- 
and anticholinergics can elicit an antagonistic response and fur-
ther hasten cognitive decline.15
Review and optimization of medication are recommended by 
specialist representative bodies.16 The widely used STOPP/START 
criteria for potentially inappropriate prescribing in older people were 
expanded in the latest version of 2014 to cover more drugs that have 
anticholinergic activity.17 The 2015 revision of the Beer’s criteria by 
the American Geriatric Society recommends avoiding anticholiner-
gics in patients with chronic cognitive impairment and delirium.18 
The Silver Book by the British Geriatric Society defines standards 
for urgent and emergency care of frail older patients and advocates 
a medicines review at the time of crisis, with particular regard to sed-
ative, psychotropic, hypotensive or anticholinergic medications.19
Little is known about how effective the recommended review of 
DAPs is in patients at risk who present acutely and how often drugs 
with anticholinergic properties are used temporarily during an ad-
mission. We investigated the impact of hospital admission on the 
anticholinergic burden and the use of relevant medications in medi-
cal patients admitted with a diagnosis of delirium, chronic cognitive 
impairment or falls. As such, our main objective was to investigate 
the possible change of the ACB from admission to discharge and the 
temporary use of DAPs. The secondary goal was to identify differ-
ences in diagnostic and demographic subgroups including death and 
readmission.
2  | METHODS
This multicentre observational study, which took place between 
October 2014 and March 2016, was conducted in 7 acute hospi-
tals in the UK, Finland, the Netherlands and Italy as collaboration 
through the Global Research on Acute Conditions Team (GREAT 
Network, www.greatnetwork.org). None of the centres involved 
changed their approach to medication review or optimization in 
preparation for this study but continued throughout with their usual 
clinical current practice.
The project was screened in accordance with the recommenda-
tions of the UK Healthcare Quality Improvement Partnership and 
the NHS Health Research Authority and categorized as a service 
evaluation.20,21 All centres registered the project with their local 
audit departments or obtained approval by their relevant institu-
tional review boards.
Each centre selected patients prospectively over a period of at 
least 1 month. We included unscheduled emergency admissions 
under the medical teams (ie, acute medicine, general internal med-
icine and geriatric medicine) with a diagnosis of chronic cognitive 
impairment or dementia, acute confusional state or delirium, or falls. 
We recorded demographics, date of admission, diagnoses that led 
to inclusion in the study, use of AChE- Is, whether a new diagnosis 
of dementia had been made by discharge, the date of discharge or 
death, and whether patients were readmitted or died within 30 days 
after discharge. To record DAPs, we adapted the 2012 revision of 
the original ACB scale.22 Medication names were translated to those 
in use in the participating centres and were grouped by indication 
and ACB. We added the opioid tramadol due to its central type- 3 
muscarinic receptor antagonism.23 The relevant medications, as well 
as each patient’s cumulative burden on admission and discharge and 
if used during the hospital stay, were recorded (Figure 1).
We compared demographic subgroups, diagnoses, length of stay 
(day 0 discharge, short stay of up to 3 days, stay up to 1 week and stay 
More than 1 in 5 patients not taking anticholinergics on admission were discharged on 
them and similar numbers saw temporary use of these medications during their admis-
sion. More than half of patients on cholinesterase- inhibitors were taking anticholinergics 
at the same time on admission, potentially directly counteracting their effects.
K E Y W O R D S
anticholinergic cognitive burden, anticholinergics, cholinesterase inhibitors, cognitive 
impairment, falls, medication review, medicines optimization
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longer than 1 week), outcomes including readmission and discharge to 
their own home. The Shapiro- Wilk test was used to test for normality, 
the Wilcoxon signed- rank test to compare the anticholinergic burden 
scores on admission and discharge, the 2 sample t test, Yates and 
Pearson’s chi- square test to analyse subgroups. Multivariate binary 
logistic regression was conducted to identify possible baseline clini-
cal, demographic and geographical confounders, including patients on 
and those not on DAPs, predicting an increase vs. decrease in ACB at 
discharge, as well as readmission and mortality. The point of statistical 
significance was set at P < .05. Statistical analysis was performed with 
RStudio version 1.0.143, apart from the multivariate binary logistic re-
gression models, where IBM spss version 22.0 was used.
3  | RESULTS AND DISCUSSION
The baseline characteristics of the 549 patients included are sum-
marized in Table 1. 60.8% of the patients were taking DAPs on ad-
mission. Mean ACB score was 2.1 (range 1- 10, SD 1.5). 19.1% of all 
patients had an ACB of 3 or more (mean = 4, range 3- 10, SD 1.3). 
There was no difference between ACB scores on admission com-
pared to discharge or death (P = .569). There was no change in ACB 
scores in 59.2% of patients. 21.1% had their ACB score reduced by 
a mean of 1.7 (range 1- 6, SD 1.1). 19.7% of patients had their ACB 
increased by a mean of 1.6 (range 1- 5, SD 1.0). 22.8% of DAP- naïve 
patients were discharged on DAPs. No predictors of a decrease in 
the ACB scores were identified (Table 2a). Patients from the UK or 
Finland were less likely to have their ACB score increased. A higher 
number of DAPs used temporarily during admission was associated 
with a higher risk of ACB score increase on discharge (OR = 1.82, 
95% CI for OR: 1.36- 2.45, P < .001; Table 2b).
Of 98 medications on the ACB scale, 56 were observed in our 
patients. Figure 2 shows each drug on admission and discharge. The 
lighter shaded bars show the percentage of patients who had each 
drug discontinued or newly commenced by discharge. In Figure 3, 
the same medications are weighted by their anticholinergic burden 
to represent the percentage of each medication on the cumulative 
burden. Seven medications with the highest individual ACB of 3 
were recorded on admission. These represent 13.8% of all recorded 
F IGURE  1 Adapted Anticholinergic Burden Scale
TABLE  1 Patient characteristics
Number of patients 549
Female (%) 58.3
Male (%) 41.7
Mean age (years) 79.6
Patients aged 65 years or older 89.8%
Admission diagnosis:
Dementia (%) 27.0
Acute delirium (%) 34.8
Falls (%) 60.3
Dementia diagnosed during admission (%) 4.9
Patients on anticholinergics (%) 60.8
Patients on cholinesterase inhibitors (%) 6.7
Mean length of stay (days) 9.3
30- day readmission rate as % of all patients 15.7
As % of all patients that were discharged/survived 16.9
Mortality during index admission in % 7.7
Mortality within 30 days post- discharge in % 4.0
The data sets were complete for all but 5 patients (0.9%) where follow- up 
information was unavailable.
     |  685WEICHERT ET al.
drugs used or 31.9% of the anticholinergic burden. 6.0% of all pa-
tients were taking at least one of them. The anticholinergic load in 
our patients was predominantly caused by medications with a low 
individual burden which were accounting for 64.9% of the total bur-
den (Table 3).
DAPs were used temporarily during the admission in 21.9% of all 
patients. Their mean ACB score was low at 0.4 (range 0- 6, SD 0.9). 
We found 26 different medications, most frequently morphine, co-
deine, haloperidol, diazepam and furosemide (Table 4).
Tramadol, which we had added in our adaption of the ACB scale, 
was only seen in 2.7% of patients on admission and was used tem-
porarily in 2.9%.
The results of our subgroup analysis are shown in Tables 5a- d.
Short stay patients (stay for a maximum of 3 days) were the 
only group that saw their ACB reduced (P = .018, Table 5d). This 
group had fewer patients on DAPs on discharge (48.4% vs 60.5%, 
P = .022), saw equal numbers of patients who had their anticholin-
ergics reduced but fewer patients who had theirs increased (8.9% 
vs 22.8%, P = .001) compared to the patients who were not short 
stay.
Patients who could not return home but were discharged to 
sheltered accommodation, residential or nursing home, were older 
than the rest of the patients (82.0 vs 76.5 years, P < .001) but did not 
differ in ACB scores. They were the only subgroup which saw a sig-
nificant increase in ACB by discharge (P = .016, Table 5d). More than 
double of these patients had their ACB increased (15.4 vs. 32.7%, 
P < .001), and they also saw a much higher temporary use of DAPs 
(in 34.6% vs 16.4% of patients, P < .001) with a higher burden of anti-
cholinergics used temporarily (mean 0.7, SD 1.2 vs mean 0.2, SD 0.6, 
P < .001) compared to those who went back home.
TABLE  2 Multivariate binary logistic regression analysis. (a) 
Increase in ACB score. (b) Decrease in ACB score. (c) Inpatient 
mortality. (d) Readmission
Odds 
ratio
95% CI for Odds 
ratio
P valueLower Upper
(a) Increase in ACB score
Age 1.01 0.99 1.04 .224
Sex 0.94 0.55 1.59 .810
UK centre 0.05 0.01 0.36 .003
Finnish centre 0.04 0.01 0.27 .001
Dutch centre 0.14 0.02 1.11 .063
Italian centre 0.47 0.06 3.86 .481
From care home 0.97 0.47 1.98 .924
Chronic cognitive 
impairment or dementia
0.63 0.28 1.45 .281
Acute delirium or 
confusional state
0.98 0.44 2.20 .962
Falls 1.08 0.47 2.52 .852
Temporary used DAPs 1.82 1.36 2.45 <.001
(b) Decrease in ACB score
Age 0.99 0.97 1.01 .372
Sex 1.01 0.62 1.63 .977
UK centre 1.30 0.27 6.37 .746
Finnish centre 0.35 0.07 1.71 .196
Dutch centre 0.78 0.12 5.02 .796
Italian centre 0.66 0.10 4.22 .663
From care home 1.26 0.67 2.38 .477
Chronic cognitive 
impairment or 
dementia
0.82 0.39 1.69 .583
Acute delirium or 
confusional state
0.61 0.29 1.25 .175
Falls 0.52 0.19 1.00 .053
Temporary used DAPs 1.13 0.83 1.52 .437
(c) Inpatient mortality
Age 1.06 1.02 1.12 .010
Sex 1.15 0.52 2.53 .736
UK centre 0.57 0.19 1.74 .322
Finnish centre 0.04 0.01 0.26 .001
Dutch centre 0.45 0.07 2.74 .387
Italian centre 0.89 0.12 3.34 .435
From care home 2.54 1.10 5.86 .029
Chronic cognitive 
impairment or 
dementia
0.66 0.25 1.76 .408
Acute delirium or 
confusional state
1.48 0.56 3.93 .430
Falls 0.45 0.16 1.28 .135
Temporary used DAPs 2.20 1.45 3.35 <.001
(Continues)
Odds 
ratio
95% CI for Odds 
ratio
P valueLower Upper
(d) Readmission
Age 1.01 0.99 1.03 .316
Sex 0.72 0.43 1.22 .221
UK centre 0.22 0.04 1.39 .107
Finnish centre 0.10 0.02 0.62 .013
Dutch centre 0.20 0.03 1.55 .122
Italian centre 0.45 0.05 3.79 .460
From care home 1.21 0.59 2.46 .599
Chronic cognitive 
impairment or 
dementia
0.44 0.18 1.05 .063
Acute delirium or 
confusional state
0.67 0.29 1.55 .352
Falls 0.64 0.27 1.51 .306
Temporary used DAPs 1.30 0.96 1.78 .095
CI, confidence interval.
TABLE  2  (Continued)
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F IGURE  2 Medications with anticholinergic properties in all patients on admission and discharge
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F IGURE  3 Medications with anticholinergic properties in all patients on admission and discharge, weighted by their individual 
anticholinergic burden
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Men in our study were younger than women (mean 77.7 vs. 
81.0 years, P = .003) and were more likely to be prescribed tempo-
rary anticholinergic drugs (26.6% vs. 18.1%, P = .022, Table 5a) with 
a higher burden of anticholinergics used temporarily (mean 0.5, SD 
1.1 vs mean 0.3, SD 0.7 P = .004).
Patients who died during index admission as well as those who 
were readmitted or died within the 30- day follow- up period did 
not differ from the rest of the patients in ACB on admission or dis-
charge/death (Table 5d). Those who died had a smaller proportion 
of patients on DAPs at death. Our data do not allow us to differen-
tiate between expected and unexpected deaths, though it is likely 
that this reduction in number of patients may be due to the delib-
erate stopping of medications in those who were not able to take 
them anymore or who had been commenced on an end of life care 
pathway.
Prescribing behaviour in all diagnostic subgroups of dementia, 
delirium or falls, as well as in those with newly diagnosed demen-
tia, was similar with no statistically significant change in ACB scores 
or number of patients on anticholinergic drugs, as well as with re-
gard to the temporary use of drugs with anticholinergic properties 
(Table 5b). Figure 4 shows the distributions of anticholinergic burden 
in each of the diagnostic groups on admission and discharge.
AChE- I (Table 5b) was found on admission in 18.2% of patients 
with a diagnosis of chronic cognitive impairment (or in 6.7% of all pa-
tients). Of these patients on procholinergics, 54.1% were also taking 
DAPs. This subgroup did not differ from the rest with regard to the 
number of patients on DAPs, ACB scores or the number of naïve pa-
tients newly started on DAPs (Table 5c). Table 6 lists DAPs found on 
admission in patients on AChE- Is. Temporary DAPs were prescribed 
less in this group compared to patients not on procholinergics on 
admission (13.5% vs 22.5% of patients, P, .001). This combination of 
antagonistic drugs makes little sense but is unfortunately frequently 
encountered.14,24 Some of the side effects of dementia drugs, such as 
urinary frequency, incontinence, diarrhoea or insomnia, may be misin-
terpreted as new comorbidities or manifestations of frailty in patients 
with cognitive impairment.25 The resulting prescribing of anticholin-
ergics will offset their efficiency and may hasten cognitive decline.
The use of drugs with the highest anticholinergic burden was low 
amongst our patients, and the anticholinergic load was caused pre-
dominantly by drugs with lesser activity. Adverse drug events are 
the result of the anticholinergic load of multiple medications rather 
than of a single drug.26 Combined anticholinergic use increases hos-
pitalizations and mortality in older people27 and hastens cognitive 
decline. For one point in the ACB, a decline in the Mini- mental State 
Examination28 (MMSE) score of 0.33 over 2 years has been sug-
gested.7 Furthermore, an increase in the cumulative ACB by one has 
been linked with a 26% increase in mortality.29
More than one- third of medications included in the ACB scale 
were not in use in our patients. This reflects the availability of these 
medications within the countries that took part in our study. In a 
globalized world with access to non- formulary drugs when travelling 
abroad or by purchasing them online via regulated or rogue pharma-
cies, we do not suggest the use of a shortened ACB scale.
Temporary medications were used in more than 1 in 5 patients. 
This was the same in all diagnostic subgroups including patients with 
an acute delirium, potentially worsening their confusion. It may be 
difficult to fully avoid these but non- pharmacological approaches to 
prevent or treat delirium including addressing the environment in 
which patients are cared for may reduce their need.30
Our study is not without limitations. Our aim was to analyse 
the impact of an acute admission on the anticholinergic burden. 
We did not record comorbidities and did not identify terminally ill 
patients or those with end- stage dementia. Overall, rates for read-
mission and mortality were nevertheless similar to those in patients 
described in large cohort studies looking at outcomes of elderly 
patients admitted.31 All participating centres were acute hospitals 
TABLE  3 Proportion of anticholinergic medications used in all 
patients on admission
ACB = 1 ACB = 2 ACB = 3
% of DAPs 84.1 2.1 13.8
% of total ACB 64.9 3.2 31.9
TABLE  4 Temporarily used medications with anticholinergic 
properties
Medication %
Morphine 28.3
Codeine 19.2
Haloperidol 15.0
Diazepam 14.2
Furosemide 14.2
Tramadol 13.3
Alprazolam 10.8
Warfarin 9.2
Hydrocortisone 6.7
Promethazine 4.2
Isosorbide 4.2
Risperidone 3.3
Digoxin 2.5
Metoprolol 2.5
Triamterene 2.5
Ranitidine 1.7
Fentanyl 1.7
Olanzapine 1.7
Carbamazepine 1.7
Chlorpheniramine 0.8
Atenolol 0.8
Prednisolone 0.8
Clozapine 0.8
Nortriptyline 0.8
Loperamide 0.8
Oxcarbazepine 0.8
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TABLE  5  (a) Gender, (b) diagnoses, (c) patients on cholinesterase inhibitors (AChE- I) and (d) other subgroups
All Female Male
(a)
% of all patients 100.0 58.3 41.7
Gender (%)
Female 58.3 100.0 0.0 P < .001
Male 41.7 0.0 100.0
Age
Mean 79.6 81.0 77.7 P = .003
SD 13.1 13.5 12.3
Patients on AChE- I on admission (%) 6.7 5.3 8.3 P = .223
Patients on DAPs on admission (%) 60.8 58.1 64.6 P = .147
ACB Score on admission
Range 0- 10 0- 8 0- 10 P = .558
Mean 1.3 1.3 1.4
SD 1.6 1.6 1.6
Patients on DAPs on discharge (%) 57.7 55.6 60.3 P = .319
ACB score on discharge
Range 0- 10 0- 8 0- 10 P = .603
Mean 1.3 1.3 1.3
SD 1.6 1.6 1.6
Patients on temporary DAPs (%) 21.9 18.1 26.6 P = .022
ACB score temp.DAPs
Range 0- 6 0- 3 0- 6
Mean 0.4 0.3 0.5
SD 0.9 0.7 1.1 P = .004
Patients who had ACB reduced (%) 21.1 21.3 21.0 P = 1.000
Patients who had ACB increased (%) 19.7 19.4 19.7 P = 1.000
Patients with no change in ACB (%) 59.2 59.4 59.4 P = 1.000
DAP naïve started on DAPs (%) 22.8 20.9 24.7 P = 1.000
ACB on admission vs discharge P = 0.569 0.760 0.512
All Dementia Delirium Falls
New 
dementia
(b)
% off all patients 100.0 27.0 34.8 60.3 4.9
Gender (%)
Female 58.3 60.8 P = .563 56.5 P = .563 60.1 P = .380 59.3 P = 1.000
Male 41.7 39.2 43.5 39.9 40.7
Age
Mean 79.6 83.7 P < .001 79.3 P = .606 79.5 P = .819 88.2 P < .001
SD 13.1 7.1 12.1 14.0 5.2
Patients on AChE- I on admission 
(%)
6.7 17.6 P < .001 5.2 P = .396 5.7 P = .329 3.7 P = 1.000
Patients on DAPs on admission: 
(%)
60.8 66.9 P = .096 64.4 P = .274 57.1 P = .026 63.0 P = .826
(Continues)
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TABLE  5  (Continued)
All Dementia Delirium Falls
New 
dementia
ACB Score on admission
Range 0- 10 0- 7 P = .144 0- 7 P = .318 0- 10 P = .134 0- 6 P = .598
Mean 1.3 1.5 1.5 1.3 1.5
SD 1.6 1.7 1.6 1.6 1.8
Patients on DAPs on discharge 
(%)
57.7 58.1 P = .993 59.7 P = .603 56.8 P = .643 59.3 P = 1.000
ACB score on discharge
Range 0- 10 0- 7 P = .452 0- 7 P = .277 0- 10 P = .346 0- 8 P = .959
Mean 1.3 1.4 1.4 1.3 1.3
SD 1.6 1.8 1.7 1.6 1.8
Patients on temporary DAPs (%) 21.9 17.6 23.6 20.8 11.1
ACB score temp.DAPs
Range 0- 6 0- 4 P = .072 0- 6 P = .186 0- 5 P = .137 0- 5 P = .433
Mean 0.4 0.3 0.4 0.3 0.3
SD 0.9 0.7 1.0 0.7 1.0
Patients who had ACB reduced 
(%)
21.1 27.0 P = .053 23.6 P = .406 17.5 P = .015 25.9 P = .506
Patients who had ACB increased 
(%)
19.7 18.9 P = .882 23.6 P = .118 17.8 P = .218 18.5 P = 1.000
Patients with no change in ACB 
(%)
59.2 54.1 P = .164 52.9 P = .041 64.7 P = .002 55.6 P = .684
DAP naïve started on DAPs (%) 22.8 28.6 P = .922 26.5 P = .887 20.4 P = 1.000 20.0 P = 1.000
ACB on admission vs discharge 
P=
0.569 0.320 0.760 0.995 0.661
All AChE- I on admission
(c)
% of all patients 100.0 6.7
Gender (%)
Female 58.3 48.6 P = .290
Male 41.7 51.4
Age
Mean 79.6 83.4 P = .001
SD 13.1 6.0
Patients on AChE- I on admission 
(%)
6.7 100.0
Patients on DAPs on admission: 
(%)
60.8 54.1 P = .483
ACB Score on admission
Range 0- 10 0- 6 P = .933
Mean 1.3 1.3
SD 1.6 1.6
Patients on DAPs on discharge 
(%)
57.7 54.1 P = .766
ACB score on discharge
Range 0- 10 0- 6 P = .809
Mean 1.3 1.2
SD 1.6 1.6
(Continues)
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TABLE  5  (Continued)
All AChE- I on admission
Patients on temporary DAPs (%) 21.9 13.5
ACB score temp.DAPs
Range 0- 6 0- 1 P < .001
Mean 0.4 0.1
SD 0.9 0.3
Patients who had ACB reduced 
(%)
21.1 13.5 P = .334
Patients who had ACB increased 
(%)
19.7 13.5 P = .446
Patients with no change in ACB 
(%)
59.2 73.0 P = .111
DAP naïve started on DAPs (%) 22.8 23.5 P = .906
ACB on admission vs discharge 
P=
0.569 0.755
All Died during admission Short stay (3 d max) Unable to return home 30 d readmission
(d)
% of all patients 100.0 7.7 22.6 18.9 15.7
Gender (%)
Female 58.3 57.1 59.7 63.5 53.5
Male 41.7 42.9 P = .965 40.3 P = .800 36.5 P = .228 46.5 P = .291
Age
Mean 79.6 84.4 78.2 82.0 79.7
SD 13.1 9.0 P = .001 13.4 P = .194 9.0 P < .001 11.9 P = .713
Patients on AChE- I on 
admission (%)
6.7 2.4 P = .394 7.3 P = .954 2.9 P = .230 7.0 P = 1.000
Patients on DAPs on 
admission: (%)
60.8 73.8 P = .104 57.3 P = .410 61.5 P = .532 68.6 P = .079
ACB Score on admission
Range 0- 10 0- 5 0- 10 0- 6 0- 7
Mean 1.3 1.6 1.3 1.3 1.5
SD 1.6 1.5 P = .309 1.8 P = .728 1.4 P = .777 1.5 P = .188
Patients on DAPs on 
discharge* (%)
57.7 59.5 P = .916 48.4 P = .022 66.3 P = .029 62.8 P = .339
ACB score on discharge*
Range 0- 10 0- 7 0- 10 0- 8 0- 8
Mean 1.3 1.3 1.1 1.6 1.5
SD 1.6 1.6 P = .898 1.7 P = .074 1.8 P = .025 1.9 P = .166
Patients on temporary 
DAPs (%)
21.9 38.1 P = .013 18.5 P = .373 34.6 P < .001 27.9 P = .059
ACB score temp.DAPs
Range 0- 6 0- 5 0- 3 0- 6 0- 6
Mean 0.4 0.8 0.3 0.7 0.4
SD 0.9 1.4 P = .030 0.6 P = .056 1.2 P < .001 0.9 P = .220
Patients who had ACB 
reduced (%)
21.1 35.7 P = .027 21.0 P = 1.000 13.5 P = .172 20.9 P = .872
(Continues)
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either at regional or at teaching hospital level. We did not look into 
potential differences of the organization of medication manage-
ment in these facilities. The clinicians involved in the project were 
also—at least in part—the same clinicians looking after the patients 
included in our study. These factors may have potentially also ac-
counted for the regional differences highlighted by the regression 
analysis, that is that for patients recruited in UK or Finnish cen-
tres, the probability for an increase in ACB score was lower. Studies 
comparing the organization of medicines review and optimization 
in different healthcare systems will be necessary to investigate this 
in future.
Our results mirror community- based studies that have shown 
that there is considerable scope for improvement of prescribing 
practices in older people.14 Theoretical models have shown that a re-
duction in anticholinergic burden can be achieved in 59% of patients 
that score at least one point on the ACB scale and that a reduction 
from a score of 3 or above to 2 is possible in 85% of the cases.32 
Various approaches to tackle anticholinergic burden have been 
suggested. For many indications of DAPs, there exist alternatives 
that allow reducing the anticholinergic load. This can include drugs 
with lesser or no anticholinergic activity or non- pharmacological 
approaches.33 The provision of guidelines and education alone do 
not seem to be sufficient to ensure best medicines review and op-
timization in older people. Random control trials have shown an 
improvement in the quality of prescribing and deprescribing via the 
use of multidisciplinary teams, geriatric case conferences, medica-
tion review by pharmacists and the use of information technology to 
support medication decisions.34
F IGURE  4 Distribution of anticholinergic burden on admission 
and discharge by diagnosis
TABLE  6 Medications with anticholinergic properties used in 
patients on procholinergic drugs on admission
Medication %
Furosemide 16.1
Alprazolam 9.7
Quetiapine 9.7
Isosorbide 6.5
Risperidone 6.5
Trazodone 6.5
Olanzapine 6.5
Ranitidine 3.2
Quinidine 3.2
Warfarin 3.2
Codeine 3.2
Fentanyl 3.2
Morphine 3.2
Aripiprazole 3.2
Venlafaxine 3.2
Amitriptyline 3.2
Clozapine 3.2
Nortriptyline 3.2
Oxybutynin 3.2
All Died during admission Short stay (3 d max) Unable to return home 30 d readmission
Patients who had ACB 
increased (%)
19.7 23.8 P = .594 8.9 P = .001 32.7 P < .001 18.6 P = 1.000
Patients with no change 
in ACB (%)
59.2 40.5 P = .015 70.2 P = .007 53.8 P = .073 60.5 P = .982
DAP naïve started on 
DAPs (%)
22.8 27.3 P = .922 15.1 P = .358 32.5 P = .100 18.5 P = .360
ACB on admission vs 
discharge P =
.569 .382 .018 .016 .944
*or at death if the patient died during the index admission
TABLE  5  (Continued)
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4  | WHAT IS NE W AND CONCLUSION
To our knowledge, this is the first multicentre study to investigate the 
effect of an acute admission on the ACB. There was no reduction in 
cumulative scores in our patients who presented as unscheduled emer-
gency admissions with a history of falls, acute delirium or dementia. 
Similar numbers of patients had their ACB reduced or increased. The 
same medications, whilst stopped in some patients, were started in oth-
ers. More than one in 5 patients who were not taking anticholinergics 
when admitted were prescribed them by discharge. This prescribing 
pattern was the same for all diagnostic subgroups. Short- stay patients 
had their ACB burden reduced by discharge. In contrast, patients who 
were not able to be discharged back to their home were the only sub-
group identified which saw a significant increase in ACB from admission 
to discharge. Despite more than 25 years of evidence and national as 
well as international recommendations, much more needs to be done to 
improve medication management in these patients. “Imperative drug-
ging – the ordering of medicine in any and every malady is no longer 
regarded as the chief function of the doctor” but “one of the first duties 
of the physician is to educate the masses not to take medicines.”35,36 
These quotes by Sir William Osler are even more valid today, nearly a 
century after his death. To substantiate them will require a joint effort 
from both primary and secondary care, through more education, more 
focused involvement from pharmacists and multidisciplinary teams, 
both in the community and in hospitals, and also by raising awareness 
in patients, their caregivers and support groups alike.
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